Tubular nephrotoxicity during long-term ifosfamide and mesna therapy
- PMID: 2574077
- DOI: 10.1007/BF00694342
Tubular nephrotoxicity during long-term ifosfamide and mesna therapy
Abstract
The nephrotoxic effects of ifosfamide were assessed in 18 children and adolescents given cumulative doses of 32-112 g/m2 (1.6 g/m2 per day in sequential 5-day courses) with the uroprotectant mesna (1.2 g/m2 per day). Tubular nephrotoxicity was evaluated by measuring the urinary concentrations of N-acetyl-beta-D-glucosaminidase (NAG), alanine aminopeptidase (AAP), and total protein before and during sequential courses of therapy. Of 15 patients who had normal levels of tubular markers before ifosfamide therapy, only 1 developed a persistent increase in baseline values of the three tubular markers with the sixth course of ifosfamide. Although transient increases in the excretion of these markers were observed during each 5-day course of ifosfamide, the magnitude did not increase over sequential courses in these 15 patients. Of the remaining three patients who had increased NAG levels before ifosfamide therapy, two showed a progressive increase in enzymuria and proteinuria, and serum creatinine concentrations increased in a single patient who had obstructive uropathy. Our data suggest that children with normal renal function can be given large cumulative amounts of ifosfamide in fractionated doses with little risk of progressive clinical nephrotoxicity.
Similar articles
-
Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna.Cancer Treat Rep. 1987 Feb;71(2):127-30. Cancer Treat Rep. 1987. PMID: 2879626
-
Cumulative renal tubular damage associated with cisplatin nephrotoxicity.Cancer Chemother Pharmacol. 1986;18(1):69-73. doi: 10.1007/BF00253068. Cancer Chemother Pharmacol. 1986. PMID: 2875808
-
Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.Anticancer Res. 2000 Sep-Oct;20(5C):3767-73. Anticancer Res. 2000. PMID: 11268452 Clinical Trial.
-
Ifosfamide, mesna, and nephrotoxicity in children.J Clin Oncol. 1993 Jan;11(1):173-90. doi: 10.1200/JCO.1993.11.1.173. J Clin Oncol. 1993. PMID: 8418231 Review.
-
Ongoing clinical studies of ifosfamide for pediatric cancer in the United States.Semin Oncol. 1996 Jun;23(3 Suppl 6):84-90. Semin Oncol. 1996. PMID: 8677456 Review.
Cited by
-
Progressive renal toxicity due to ifosfamide.Arch Dis Child. 1991 Aug;66(8):966-70. doi: 10.1136/adc.66.8.966. Arch Dis Child. 1991. PMID: 1718222 Free PMC article.
-
Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.Cancer Chemother Pharmacol. 1991;28(6):455-60. doi: 10.1007/BF00685822. Cancer Chemother Pharmacol. 1991. PMID: 1934249
-
Glomerular filtration rate and prevalence of chronic kidney disease in Wilms' tumour survivors.Pediatr Nephrol. 2011 May;26(5):759-66. doi: 10.1007/s00467-011-1759-3. Epub 2011 Jan 29. Pediatr Nephrol. 2011. PMID: 21279390 Free PMC article.
-
Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy.Cancer Chemother Pharmacol. 1993;31(5):387-94. doi: 10.1007/BF00686153. Cancer Chemother Pharmacol. 1993. PMID: 8431973
-
Ifosfamide nephrotoxicity in paediatric cancer patients.Eur J Pediatr. 1994 Feb;153(2):90-4. doi: 10.1007/BF01959214. Eur J Pediatr. 1994. PMID: 8157032
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Miscellaneous